Nursing Medical News about Ovarian Neoplasms Maintenance Medication Therapy Management

Your Unread Messages

See All

Tracy Hampton, PhD

Clinical Trial Watch

Palliative Care Benefits Patients with Advanced Cancer

Roberta Buell, MBA
HHS Weighs In On Health Reform

Dorothy J. Schirf, MD

Technology Advances

Radiosurgery Trial Sparks Optimism for Early Lung Cancer

Sara Hartley

Cancer Science

Hitting Chronic Lymphocytic Leukemia Where it Hurts

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Use of Antiemetic Agents in Acute Gastroenteritis

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Current status of maintenance therapy for advanced ovarian cancer
International Journal of Women's Health, 11/04/09

Hope JM et al. – Even after countered with and responding to maximal surgical and chemotherapy efforts, advanced ovarian cancer usually ultimately recurs. One strategy employed to forestall recurrence is maintenance chemotherapy, an extension of treatment following a complete response to conventional measures. Many agents have been studied and many more are currently under investigation in maintenance regimens. While phase III data suggest that taxane maintenance prolongs progression–free survival, no overall survival benefit has been established. This article reviews the current status of maintenance therapy for advanced ovarian cancer, including phase III evidence and new and upcoming trials.

<< Previous
Usefulness of inspiratory capacity measurement in COPD patients...

Next >>
Evidence-based care for breast cancer survivors: Communicating...